Literature DB >> 9883804

Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes.

S D Mundle1, A Ali, J D Cartlidge, S Reza, S Alvi, M M Showel, B Y Mativi, V T Shetty, P Venugopal, S A Gregory, A Raza.   

Abstract

We previously reported excessive apoptosis and high levels of tumor necrosis factor-alpha (TNF-alpha) in the bone marrows of patients with myelodysplastic syndromes (MDS), using histochemical techniques. The present studies provide further circumstantial evidence for the involvement of TNF-alpha in apoptotic death of the marrow cells in MDS. Using our newly developed in situ double-labeling technique that sequentially employs DNA polymerase (DNA Pol) followed by terminal deoxynucleotidyl transferase (TdT) to label cells undergoing apoptosis, we have characterized DNA fragmentation patterns during spontaneous apoptosis in MDS bone marrow and in HL60 cells treated with TNF-alpha or etoposide (VP16). Clear DNA laddering detected by gel electrophoresis in MDS samples confirmed the unique length of apoptotic DNA fragments (180-200 bp). Surprisingly, however, phenotypically heterogeneous population of MDS cells as well as the homogenous population of HL60 cells showed three distinct labeling patterns after double labeling--only DNA-Pol reaction, only TdT reaction, and a combined DNA Pol + TdT reaction, albeit in different cohorts of cells. Each labeling pattern was found at all morphological stages of apoptosis. MDS mononuclear cells, during spontaneous apoptosis in 4 hr cultures, showed highest increase in double-labeled cells (DNA Pol + TdT reaction). Interestingly, this was paralleled by TNF-alpha-induced apoptosis in HL60 cells. In contrast, VP16 treatment of HL60 cells led to increased apoptosis in cells showing only TdT reaction. The double-labeling technique was applied to normal bone marrow and peripheral blood mononuclear cells after treatment with known endonucleases that specifically cause 3' recessed (BamHI), 5' recessed (PstI), or blunt ended (DraI) double-stranded DNA breaks. It was found that the DNA-Pol reaction in MDS and HL60 cells corresponds to 3' recessed DNA fragments, the TdT reaction to 5' recessed and/or blunt ended fragments, and a combined "DNA Pol + TdT reaction" corresponds to a copresence of 3' recessed with 5' recessed and/or blunt ended fragments. Clearly, therefore, apoptotic DNA fragments, in spite of a unique length, may have differently staggered ends that could be cell (or tissue) specific and be selectively triggered by different inducers of apoptosis. The presence of TNF-alpha-inducible apoptotic DNA fragmentation pattern in MDS supports its involvement in these disorders and suggests that anti-TNF-alpha (or anticytokine) therapy may be of special benefit to MDS patients, where no definitive treatment is yet available.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9883804     DOI: 10.1002/(sici)1096-8652(199901)60:1<36::aid-ajh7>3.0.co;2-#

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  8 in total

Review 1.  Myelodysplasia and apoptosis: new insights into ineffective erythropoiesis.

Authors:  A A van de Loosdrecht; E Vellenga
Journal:  Med Oncol       Date:  2000-02       Impact factor: 3.064

Review 2.  Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes.

Authors:  R Tehranchi
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

3.  Treatment of myelodysplastic syndrome with cyclosporin A.

Authors:  Shuchang Chen; Bin Jiang; Wanming Da; Ming Gong; Mei Guan
Journal:  Int J Hematol       Date:  2007-01       Impact factor: 2.490

Review 4.  The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes.

Authors:  Azra Raza; Naomi Galili
Journal:  Nat Rev Cancer       Date:  2012-12       Impact factor: 60.716

Review 5.  Improving Treatment for Myelodysplastic Syndromes Patients.

Authors:  Julia Montoro; Aslihan Yerlikaya; Abdullah Ali; Azra Raza
Journal:  Curr Treat Options Oncol       Date:  2018-10-25

6.  The biology of myelodysplastic syndromes: unity despite heterogeneity.

Authors:  Azra Raza; Raymond Cruz; Tahir Latif; Siddhartha Mukherjee; Naomi Galili
Journal:  Hematol Rep       Date:  2010-06-23

7.  Usefulness of Adalimumab for Treating a Case of Intestinal Behçet's Disease With Trisomy 8 Myelodysplastic Syndrome.

Authors:  Masamichi Kimura; Yoshihisa Tsuji; Masako Iwai; Masahiro Inagaki; Ali Madian; Takuya Yoshino; Minoru Matsuura; Hiroshi Nakase
Journal:  Intest Res       Date:  2015-04-27

Review 8.  Acquired myelodysplasia or myelodysplastic syndrome: clearing the fog.

Authors:  Ethan A Natelson; David Pyatt
Journal:  Adv Hematol       Date:  2013-10-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.